These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768 [TBL] [Abstract][Full Text] [Related]
24. Acute left ventricular failure following melphalan and fludarabine conditioning. Ritchie DS; Seymour JF; Roberts AW; Szer J; Grigg AP Bone Marrow Transplant; 2001 Jul; 28(1):101-3. PubMed ID: 11498753 [TBL] [Abstract][Full Text] [Related]
26. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Morecki S; Gelfand Y; Nagler A; Or R; Naparstek E; Varadi G; Engelhard D; Akerstein A; Slavin S Bone Marrow Transplant; 2001 Aug; 28(3):243-9. PubMed ID: 11535991 [TBL] [Abstract][Full Text] [Related]
27. [Significance of intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation for treatment of acute leukemias]. Shigematsu A Rinsho Ketsueki; 2011 Aug; 52(8):667-73. PubMed ID: 21897073 [No Abstract] [Full Text] [Related]
28. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990 [TBL] [Abstract][Full Text] [Related]
29. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141 [TBL] [Abstract][Full Text] [Related]
30. Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome. Wais V; Kündgen L; Bohl SR; von Harsdorf S; Schlenk RF; Döhner K; Teleanu V; Bullinger L; Nguyen TM; Drognitz K; Moulin JC; Binnenhei M; Bentz M; Döhner H; Bunjes D; Kuchenbauer F; Ringhoffer M Bone Marrow Transplant; 2018 Jan; 53(1):94-96. PubMed ID: 29131153 [No Abstract] [Full Text] [Related]
31. Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas. Castagna L; Bertuzzi A; Nozza A; Siracusano L; Balzarotti M; Magagnoli M; Sarina B; Timofeeva I; Sinnone M; Grimoldi MG; Farè M; Santoro A Bone Marrow Transplant; 2002 Aug; 30(4):207-14. PubMed ID: 12203136 [TBL] [Abstract][Full Text] [Related]
32. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Wäsch R; Reisser S; Hahn J; Bertz H; Engelhardt M; Kunzmann R; Veelken H; Holler E; Finke J Bone Marrow Transplant; 2000 Aug; 26(3):243-50. PubMed ID: 10967561 [TBL] [Abstract][Full Text] [Related]
33. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Hoffman R; Sossman J Bone Marrow Transplant; 2003 Sep; 32(5):471-6. PubMed ID: 12942092 [TBL] [Abstract][Full Text] [Related]
34. Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma. Papadopoulos KP; Noguera-Irizarry W; Wiebe L; Hesdorffer CS; Garvin J; Nichols GL; Vahdat LH; Lo KM; Skerrett D; Bernstein D; Sharpe E; Savage DG Bone Marrow Transplant; 2005 Sep; 36(6):491-7. PubMed ID: 16044139 [TBL] [Abstract][Full Text] [Related]
35. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Martínez C; Carreras E; Rovira M; Urbano-Ispizua A; Esteve J; Perales M; Fernández F; Montserrat E Bone Marrow Transplant; 2000 Sep; 26(6):677-9. PubMed ID: 11035375 [TBL] [Abstract][Full Text] [Related]
36. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
37. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation. Ritchie DS; Szer J; Roberts AW; Shuttleworth P; Grigg AP Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202 [TBL] [Abstract][Full Text] [Related]
38. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794 [TBL] [Abstract][Full Text] [Related]
39. Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis. Chen Y; Xu LP; Zhang XH; Chen H; Wang FR; Liu KY; Qin J; Yang YL; Huang XJ Bone Marrow Transplant; 2018 Jun; 53(6):770-773. PubMed ID: 29725109 [No Abstract] [Full Text] [Related]
40. [Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies]. Hansz J Pol Arch Med Wewn; 2001; 105 Suppl():173-5. PubMed ID: 12412244 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]